An article authored by Harriet Edwards, Associate Director of Regulatory Affairs at Boyds, has been published in Cell & Gene Therapy Insights.
In the viewpoint article: ‘2024: the year of the genome editing technologies?’ Harriet looks at the current landscape for genome editing, the regulation surrounding it, and key considerations for regulators and developers as the area continues to progress.
Click here to read the full article in BioInsights: Cell & Gene Therapy Insights Journal.
With over 10 years of experience in leading and supporting regulatory projects and business critical activities, Harriet is an award-winning regulatory professional and chartered scientist. Harriet provides strategic and operational regulatory advice to help guide clients’ drug development journeys across a range of therapeutic applications and regions including the USA, EU, and APAC. She has also worked across development phases from early clinical development through to lifecycle management.
Contact the Boyds team to find out more about the regulatory affairs services we can provide.
